DSpace Repository

25 years of the WHO essential medicines lists: progress and challenges.

Show simple item record

dc.contributor Boston University School of Public Health, Boston, MA 02118, USA. richardl@bu.edu <richardl@bu.edu>
dc.creator Laing, R
dc.creator Waning, B
dc.creator Gray, A
dc.creator Ford, N
dc.creator 't Hoen, E
dc.date 2003-05-17
dc.date.accessioned 2017-01-31T07:11:01Z
dc.date.available 2017-01-31T07:11:01Z
dc.identifier 25 years of the WHO essential medicines lists: progress and challenges. 2003, 361 (9370):1723-9 Lancet
dc.identifier 0140-6736
dc.identifier 12767751
dc.identifier 10.1016/S0140-6736(03)13375-2
dc.identifier http://hdl.handle.net/10144/28005
dc.identifier http://fieldresearch.msf.org/msf/handle/10144/28005
dc.identifier Lancet
dc.identifier.uri http://dspace.mediu.edu.my:8181/xmlui/handle/10144/28005
dc.description The first WHO essential drugs list, published in 1977, was described as a peaceful revolution in international public health. The list helped to establish the principle that some medicines were more useful than others and that essential medicines were often inaccessible to many populations. Since then, the essential medicines list (EML) has increased in size; defining an essential medicine has moved from an experience to an evidence-based process, including criteria such as public-health relevance, efficacy, safety, and cost-effectiveness. High priced medicines such as antiretrovirals are now included. Differences exist between the WHO model EML and national EMLs since countries face varying challenges relating to costs, drug effectiveness, morbidity patterns, and rationality of prescribing. Ensuring equitable access to and rational use of essential medicines has been promoted through WHO's revised drug strategy. This approach has required an engagement by WHO on issues such as the effect of international trade agreements on access to essential medicines and research and development to ensure availability of new essential medicines.
dc.language en
dc.publisher Elsevier
dc.rights Reproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/[/url] for further relevant comment.
dc.title 25 years of the WHO essential medicines lists: progress and challenges.

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account